Penetration of cefazolin into pleural fluid

Area of Science:

• Pharmacology
• Infectious Diseases
• Pulmonology

Background:

• Respiratory tract infections are frequently caused by bacteria such as Staphylococcus pneumoniae, Streptococcus, Klebsiella, and Haemophilus influenzae.
• Cefazolin is a first-generation cephalosporin antibiotic with activity against Gram-positive bacteria and some Gram-negative bacteria.
• Effective antibiotic penetration into the pleural space is crucial for treating thoracic infections.

Purpose of the Study:

• To determine cefazolin concentrations in pleural fluid following single intramuscular and intravenous doses.
• To compare achieved cefazolin levels with minimal inhibitory concentrations (MICs) for common respiratory pathogens.
• To evaluate the potential efficacy of cefazolin in treating lung infections involving the pleural space.

Main Methods:

• 16 patients with lung pathology undergoing thoracic fluid aspiration received either 500 mg cefazolin intramuscularly or 1 g intravenously.
• Pleural fluid and serum samples were collected at 30, 60, 120, and 240 minutes post-administration.
• Cefazolin concentrations were quantified, and compared to established MIC values for relevant bacteria.

Main Results:

• Variable cefazolin levels were observed in both serum and pleural fluid.
• Pleural fluid cefazolin concentrations generally surpassed MICs for Staphylococcus pneumoniae, Staphylococcus species, and group A beta-hemolytic streptococcus.
• Achieved levels also exceeded MICs for most tested Klebsiella and Haemophilus influenzae strains.

Conclusions:

• Despite high protein binding, cefazolin achieves therapeutic concentrations in pleural fluid.
• These concentrations are sufficient to inhibit common bacteria implicated in respiratory tract infections.
• Cefazolin demonstrates potential as an effective treatment option for thoracic infections caused by susceptible organisms.